Scientists at Vector have done the unthinkable: they have created a vaccine against human immunodeficiency virus (HIV). First phase clinical trials just completed and 100 percent of volunteers were found to have antibodies against the virus that leads to AIDS.
According to Vector:
HIV-specific antibodies and cytotoxic T-lymphocytes after double vaccination were recorded in 100% of volunteers, and antibodies neutralizing HIV pseudoviruses in 80%
Tests were carried out with 240 volunteers, who experienced no side effects, at facilities in the city of Novosibirsk.
Vector Federal Budgetary Institution of Science State Research Center of Virology and Biotechnology is a non profit research center funded by the Russian government charged with the mission of scientific and practical support for countering global infectious threats.